Select Present & Past Relationships
Applied Proteomics Inc. (API) is advancing the application of proteomics to the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care. API has developed a proteomics platform solution to make protein-based biomarker discovery possible as a replicable, industrial application ready to be applied to health diagnostic problems. API is currently advancing several internal diagnostic development programs.
Read in Fast Company how API is Finding Diseases Faster, With A Brand-New Kind Of Blood Test.
aTyr’s mission is to improve patient care with innovative biologic drugs based on the unique biology of Physiocrines. Physiocrines are natural, endogenous human proteins that function as extracellular signals, and have therapeutic applications varying from hematology, inflammation, metabolic disorders, muscle disease, neurology and vascular disorders.
Read in Xconomy about how aTyr is Looking to Strike a Balance between Non-profits and Really Big For-Profits.
Epic Sciences, Inc. is a privately held company that is developing new diagnostic tests to improve and personalize the treatment and management of cancer. Epic was founded on a powerful platform to identify and characterize rare cells, including circulating tumor cells (CTCs). Epic has partnered with numerous pharmaceutical companies, major cancer centers, the National Cancer Institute (NCI) and the National Institutes of Health (NIH), to advance this technology to improve clinical oncology and cancer therapeutic development. With these collaborations, Epic is developing a robust commercial platform with a strong and diverse pipeline of companion diagnostic products.
Read Epic’s front page business section article about raising $13 million in The San Diego Union-Tribune.
Fate Therapeutics is interrogating adult stem cell biology and applying induced pluripotent stem cell (iPSC) technology to develop stem cell modulators (SCMs), small molecule or biologic compounds that guide cell fate for therapeutic purposes. The Company’s award-winning, proprietary iPSC technology incorporates the most advanced viral, small molecule and protein reprogramming methods and offers a highly efficient platform to recapitulate human physiology for commercial scale drug discovery and therapeutic use. The Company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.
Fate’s innovative approach has been recognized by various organizations and publications.
Invetech has been creating breakthrough products and custom automation systems for more than 30 years. With more than 200 staff, and experience drawn from over 5,000 projects, Invetech delivers product design and development, contract manufacturing and custom automation services to a range of global market sectors including diagnostics, life sciences, medical devices, cleantech, industrial and consumer products. Operating out of locations in North America, Europe and Asia Pacific, clients range from start-ups to multi-nationals.
See how Invetech helped Coco-Cola develop the award-winning Fountain of the Future.
Organovo (OTCQB: ONVO) is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. The company’s NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types. Organovo’s NovoGen MMX Bioprinter(TM) was selected as one of the “Best Inventions of 2010″ by TIME Magazine. Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development. Organovo’s bioprinting technology can also be developed to create surgical tissues as direct therapy.
Watch a video on Wall Street Journal of CEO Keith Murphy describing the impact of bioprinting.
Survivor Beach and the Luau & Longboard Invitational
Each August, an all volunteer committee puts on the Moores UCSD Cancer Center Luau & Longboard Invitational and raises much needed funds for cancer research and care. Jessica Yingling founded Survivor Beach in 2007 to increase cancer awareness and honor all survivors and supporters in their fight against cancer
These events represent one of the most successful surfing fundraisers and have donated more than $5 million for the Moores UCSD Cancer Center to translate cutting edge research into better treatments for cancer.